在感染携带L74V或与胸苷相关突变的病毒的病例中，停用抗逆转录病毒治疗后出现的不同病毒反弹情况。
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.
作者信息
de Mendoza Carmen, Paxinos Ellen, Barreiro Pablo, Camino Nuria, Núñez Marina, Soriano Vincent
机构信息
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
出版信息
J Clin Microbiol. 2004 Feb;42(2):862-6. doi: 10.1128/JCM.42.2.862-866.2004.
Abstract
A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.
摘要
共有76例患者在接受1年维持治疗后停止使用去羟肌苷加羟基脲治疗。在10例携带L74V突变的患者中观察到最大的人类免疫缺陷病毒（HIV）-RNA反弹，且携带该突变的病毒迅速减少。相比之下，12例携带胸苷相关突变的受试者的病毒反弹明显不那么明显（P<0.01）；这些突变在所有情况下均持续存在。因此，在去羟肌苷治疗期间选择L74V突变可能会损害体内HIV的复制。
相似文献
1
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.在感染携带L74V或与胸苷相关突变的病毒的病例中，停用抗逆转录病毒治疗后出现的不同病毒反弹情况。
J Clin Microbiol. 2004 Feb;42(2):862-6. doi: 10.1128/JCM.42.2.862-866.2004.
2
T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
J Infect Dis. 2002 Feb 15;185(4):448-55. doi: 10.1086/338831. Epub 2002 Jan 31.
3
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.去羟肌苷与羟基脲联合用药的短期抗HIV活性
Antivir Ther. 1996 Aug;1(3):189-93.
4
Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.司他夫定加去羟肌苷用于血浆HIV RNA低于每毫升50,000拷贝的无症状HIV感染儿童的疗效和安全性。
HIV Clin Trials. 2002 Jan-Feb;3(1):9-16. doi: 10.1310/FAJF-7A8G-QAR4-Q0X5.
5
6
Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.羟氯喹、羟基脲和去羟肌苷作为初始治疗用于病毒载量低的HIV感染患者：144周后的安全性、疗效和耐药情况
HIV Med. 2005 Jan;6(1):13-20. doi: 10.1111/j.1468-1293.2005.00259.x.
7
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.HIV-1 Vpr 中的 E17A 突变与胸苷类似物突变协同赋予对去羟肌苷的耐药性。
Antiviral Res. 2012 Jan;93(1):167-74. doi: 10.1016/j.antiviral.2011.11.008. Epub 2011 Nov 25.
8
Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.血液中与细胞相关的HIV-1 RNA作为淋巴结病毒载量的指标。瑞士HIV队列研究。
J Infect Dis. 1999 Sep;180(3):850-3. doi: 10.1086/314932.
9
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.人类免疫缺陷病毒1型逆转录酶中的L74V突变可抵消与胸苷类似物耐药性突变相关的齐多夫定单磷酸增强切除作用。
Antimicrob Agents Chemother. 2005 Jul;49(7):2648-56. doi: 10.1128/AAC.49.7.2648-2656.2005.
10
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?对去羟肌苷加羟基脲联合抗逆转录病毒疗法的系统评价：非洲艾滋病毒/艾滋病问题的部分解决方案？
Int J Infect Dis. 2001;5(1):43-8. doi: 10.1016/s1201-9712(01)90048-7.
引用本文的文献
1
Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.接受针对人类免疫缺陷病毒1型逆转录酶的核苷和核苷酸药物组合治疗的患者中病毒突变选择模式的变化。
Antimicrob Agents Chemother. 2005 May;49(5):1671-8. doi: 10.1128/AAC.49.5.1671-1678.2005.
本文引用的文献
1
Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.羟基脲加去羟肌苷作为长期成功接受高效抗逆转录病毒治疗的HIV感染患者的维持疗法。
HIV Clin Trials. 2003 Nov-Dec;4(6):361-71. doi: 10.1310/4GMU-AG3T-Q3CC-GE5D.
2
Drug resistance mutations in HIV-1.HIV-1中的耐药性突变
Top HIV Med. 2003 May-Jun;11(3):92-6.
3
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.1型人类免疫缺陷病毒感染成人的抗逆转录病毒药物耐药性检测：美国国际艾滋病学会专家组2003年建议
Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23.
4
Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.
AIDS. 2002 Nov 22;16(17):2342-4. doi: 10.1097/00002030-200211220-00018.
5
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.在慢性HIV感染中，通过结构化治疗中断刺激HIV特异性细胞免疫未能增强病毒控制。
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7.
6
Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.中断抗逆转录病毒疗法以增强对慢性HIV-1感染的免疫控制：有风险而无益处。
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13377-8. doi: 10.1073/pnas.212518999. Epub 2002 Oct 7.
7
Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.人类免疫缺陷病毒感染成人接受蛋白酶抑制剂治疗长期病毒学失败期间表型药物敏感性和病毒复制能力的演变
J Virol. 2002 Nov;76(21):11104-12. doi: 10.1128/jvi.76.21.11104-11112.2002.
8
Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
J Med Virol. 2002 Sep;68(1):1-6. doi: 10.1002/jmv.10162.
9
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.2002年成人HIV感染的抗逆转录病毒治疗：美国国际艾滋病学会专家组的更新建议
JAMA. 2002 Jul 10;288(2):222-35. doi: 10.1001/jama.288.2.222.
10
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.
AIDS. 2002 Apr 12;16(6):895-9. doi: 10.1097/00002030-200204120-00009.
Zotero 插件